Table 1 Summary of clinical trials with CD47-targeting antibodies

Magrolimab (Hu5F9-G4)

Gilead Science (Forty-Seven)

Humanized, IgG4

Solid Tumor

monotherapy

Phase I

NCT02216409

88 participants, Completed

AML, MDS

monotherapy

Phase I

NCT02678338

20 participants, Completed

R/R B-cell NHL

Rituximab, Rituximab+Gemcitabine+Oxaliplatin

Phase I/II

NCT02953509

178 participants, Active, Not Recruiting

Colorectal Neoplasms

Cetuximab

PhaseI

NCT02953782

78 participants, Completed

AML, MDS

Monotherapy, Azacitidine

Phase I

NCT03248479

287 participants, Active Not Recruiting

NHL, DLBC

Acalabrutinib and rituximab

Phase I

NCT03527147

30 participants, Completed

Ovarian cancer

Avelumab

Phase I

NCT03558139

34 participants, Completed

Urothelial carcinoma

Atezolizumab, Venetoclax

Phase I/II

NCT03869190

645 participants, Recruiting

R/R AML

Atezolizumab

Phase I

NCT03922477

13 participants, Terminated

R/R AML

Azacitidine and/or Venetoclax

Phase I/II

NCT04435691

98 participants, Recruiting

R/R Indolent B-cell Malignancies

Obinutuzumab and Venetoclax

Phase I

NCT04599634

76 participants, Suspended

TP53 mutant AML

Azacitidine and/or Venetoclax

Phase III

NCT04778397

346 particiants,Not recruiting

R/R cHL

Pembrolizumab

Phase II

NCT04788043

24, participants, Not yet  recruiting

T cell lymphoma

Mogamulizumab

Phase I/II

NCT04541017

18 participants, Suspended

Neuroblastoma or Relapsed Osteosarcoma

Dinutuximab

Phase I

NCT04751383

82 participants, Recruiting

Ligufalimab (AK117)

Akesobio Biopharma

Humanized, IgG4

Neoplasms Malignant

monotherapy

Phase I

NCT04349969

159 participants, Recruiting

Neoplasms Malignant

monotherapy

Phase I

NCT04728334

162 participants, Recruiting

MDS

Azacitidine

Phase I/II

NCT04900350

190 participants, Recruiting

AML

Azacitidine

Phase Ib/II

NCT04980885

160 participants, Recruiting

Advanced Malignant Tumors

AK112 + chemotherapy

Phase Ib/II

NCT05214482

160 participants, Recruiting

Locally Advanced and Metastatic TNBC

AK112 ± Nab-Paclitaxel/ Paclitaxel)

Phase I

NCT05227664

80 participants, Not yet recruiting

Advanced Malignant Tumors

AK112 ± (Caboplatin+Cisplatin+ 5-Fluorouracil)

Phase Ib/II

NCT05229497

114 participants, Not yet recruiting

Advanced Malignant Tumors

AK104 + Oxaliplatin±Cisplatin±Paclitaxel±5-FU

Phase Ib/II

NCT05235542

130 participants, Not yet recruiting

Lemzoparlimab (TJC4)

I-Mab BIOPARMA

Human, IgG4

Solid tumors, lymphoma

Pembrolizumab and Rituximab

Phase I

NCT03934814

116 participants, Recruiting

AML, MDS

monotherapy

Phase I/II

NCT04202003

80 participants, Recruiting

Multiple myeloma

Dexamethasone+Pomalidomide±Carfilzomib, Dexamethasone+Pomalidomide+Daratumumab

Phase Ib

NCT04895410

163 participants, Recruiting

AML, MDS

Azacitidine±Venetoclax

Phase Ib

NCT04912063

80 participants, Recruiting

Advanced Solid Tumor

toripalimab

Phase I/II

NCT05148533

96 participants, Recruiting

AO-176

Arch Oncology

Humanized, IgG2

Solid Tumor

Monotherapy,+Paclitaxel, Pembrolizumab

Phase I/II

NCT03834948

183 participants, Recruiting

R/R Multiple Myeloma

Dexamethason±Bortezomib

Phase I/II

NCT04445701

102 participants, Recruiting

CC-90002

Celgene (Inhibrx)-BMS

Humanized, IgG4

Hematologic Neoplasms

monotherapy, Rituximab

Phase I

NCT02367196

60 participants, Completed

Leukemia, Myeloid, AMDS

monotherapy

Phase I

NCT02641002

28 participants, Terminated

SGN-CD47M

Seagen Inc.

Humanized, IgG4

solid tumor

monotherapy

Phase I

NCT03957096

16 participants, Terminated

IBI188

Innovent Biologics, Inc.

Human, IgG4

Advanced Malignancies

monotherapy, Rituximab

Phase Ia

NCT03717103

49 participants, Active, not recruiting

Advanced Malignancies

monotherapy

Phase I

NCT03763149

20 participants, Recruiting

AML

azacitidine

Phase Ib

NCT04485052

126 participants, Recruiting

Higher Risk MDS

azacitidine

Phase I

NCT04485065

12 participants, Recruiting

Solid Tumors,

Lung Adenocarcinoma,

Osteosarcoma

Sintilimab, Cisplatin/Carboplatin+Bevacizumab+Pemetrexed, GM-CSF

Phase Ib

NCT04861948

120 participants, Recruiting

MDS

Azacitidine

Phase Ib

NCT04511975

32 participants, Suspended

SHR-1603

HENGRUI Medicine

Human, IgG4

Advanced Cancer

monotherapy

Phase I

NCT03722186

128 participants, Suspended (Business Decision)

SRF231

Surface Oncology

Human IgG4

Advanced Solid Cancers, Hematologic Cancers

monotherapy

Phase I/Ib

NCT03512340

148 participants, Completed

ZL-1201

ZAI lab

Humanized,

IgG4

Locally Advanced Solid Tumor

monotherapy

Phase I

NCT04257617

66 participants, Recruiting

IMC-002

ImmuneOncia Therapeutics

Human

Solid Tumor, Lymphoma

monotherapy

Phase I

NCT04306224

24 participants, Recruiting

Advanced Cancer

monotherapy

Phase I

NCT05276310

24 participants, Not yet recruiting